Compare KRYS & CIFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KRYS | CIFR |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | 295 | 66 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 6.7B |
| IPO Year | 2017 | N/A |
| Metric | KRYS | CIFR |
|---|---|---|
| Price | $340.21 | $27.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $297.60 | $24.91 |
| AVG Volume (30 Days) | 294.7K | ★ 23.1M |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $389,130,000.00 | N/A |
| Revenue This Year | $38.74 | $12.29 |
| Revenue Next Year | $32.53 | $240.53 |
| P/E Ratio | $187.67 | ★ N/A |
| Revenue Growth | ★ 33.94 | N/A |
| 52 Week Low | $130.50 | $4.29 |
| 52 Week High | $356.50 | $30.14 |
| Indicator | KRYS | CIFR |
|---|---|---|
| Relative Strength Index (RSI) | 65.25 | 60.96 |
| Support Level | $253.89 | $13.20 |
| Resistance Level | N/A | $28.62 |
| Average True Range (ATR) | 12.77 | 2.49 |
| MACD | 2.68 | 0.26 |
| Stochastic Oscillator | 72.67 | 71.69 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Cipher Digital Inc is focused on high-performance computing (HPC) data center development and operations. It is engaged in developing and operating data centers designed for HPC workloads. Its operations include managing power assets and capital allocation in response to market conditions and demand for AI-related computing capacity.